Top 7 Blue-Chip Stocks With The Best Return Potential Going Into 2025
The year 2024 saw the U.S. stock market make new records, with major indices breaching key milestones. While many stocks ...
Future Market Insights1d
Global Market for Barret’s Esophagus with Dysplasia Treatment to reach USD 7.54 million by 2033, expanding at a 5.3% CAGR: FMI Study
The global market for barrett’s esophagus with dysplasia treatment is poised for significant growth, with a projected ...
Merck & Co. Inc. stock rises Tuesday, still underperforms market
Shares of Merck & Co. Inc. MRK inched 0.08% higher to $99.45 Tuesday, on what proved to be an all-around favorable trading ...
Local vaccine biotech secures $50M Merck investment
A Fremont pharmaceutical company received an investment of approximately $50 million — about $3.56 per share — in a private ...
Future Market Insights2d
Global Molluscum Contagiosum (MC) Treatment Market Set for Exponential Growth to Reach USD 4.89 Billion by 2033
Treatment Market. According to a recent market analysis conducted by Future Market Insights, the global molluscum contagiosum ...
Merck to discontinue drug for bacterial infection
Merck will discontinue its drug for a bacterial infection that can lead to fatal diarrhea, the U.S. Food and Drug ...
bovnews2d
Merck & Co Inc (MRK) Stock Settles at $98.05: What’s Contributing to This Price Point?
On Friday, Merck & Co Inc (MRK) stock saw a decline, ending the day at $98.05 which represents a decrease of $-1.47 or -1.48% from the prior close of $99.52. The stock opened at $98.83 and touched a ...
Merck: A Low-Hanging Fruit To Pick
Merck, a leading global pharmaceutical company that produces a range of medicines, vaccines, and animal healthcare products, ...
FierceBiotech2d
Sanofi pays SK bioscience €50M as children's pneumococcal vaccine enters phase 3
Sanofi is handing SK bioscience 50 million euros ($52 million) as the longtime partners take their next-gen pneumococcal ...
Is Merck the Next Big Weight-Loss Stock?
And that's why Merck could credibly become the next big weight-loss stock. Before you rush to go buy shares of Merck, ...
Merck-AstraZeneca breast cancer drug reduces risk of death by 28% in patients diagnosed early, clinical trial shows
About 87.5% of patients treated with the drug were alive after six years, compared to 83.2% who received a placebo.
Strategic Moves in Cardiometabolic Space: Merck’s Buy Rating for Innovative Combination Therapies
Jefferies analyst Akash Tewari has maintained their bullish stance on MRK stock, giving a Buy rating on December 18.Pick the best stocks and ...